Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
Figure 4
Effects of tozasertib on the viability of neuroblastoma cells in combination with the MDM2 inhibitor nutlin-3.
Neuroblastoma cells were treated for five days with tozasertib, nutlin-3, or their combination. Cell viability was determined by MTT assay. The drug concentrations were: UKF-NB-3, tozasertib 6 nM, Nutlin-3 0.625 µM; IMR-32, tozasertib 6 nM, Nutlin-3 1.25 µM; UKF-NB-3rCDDP1000, tozasertib 6 nM, Nutlin-3 1.25 µM; UKF-NB-3rDOX20, tozasertib 156 nM, Nutlin-3 2.5 µM; UKF-NB-3rNutlin10µM, tozasertib 156 nM, Nutlin-3 5 µM; UKF-NB-3rVCR10, tozasertib 156 nM, Nutlin-3 5 µM. * P<0.05 relative to either single treatment.